Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact
Disease surveillance data are needed to monitor trends in disease activity, inform decision-making in public health and evaluate disease prevention/control measures. The Sistema Regional de Vacunas (SIREVA) supports laboratory-based surveillance of invasive pneumococcal disease (IPD) in Latin Americ...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1972709 |
| _version_ | 1797673306276495360 |
|---|---|
| author | Javier Nieto Guevara Adriana Guzman-Holst |
| author_facet | Javier Nieto Guevara Adriana Guzman-Holst |
| author_sort | Javier Nieto Guevara |
| collection | DOAJ |
| description | Disease surveillance data are needed to monitor trends in disease activity, inform decision-making in public health and evaluate disease prevention/control measures. The Sistema Regional de Vacunas (SIREVA) supports laboratory-based surveillance of invasive pneumococcal disease (IPD) in Latin American countries, providing information on identification, distribution, and anti-microbial susceptibility of pneumococcal strains. We estimated the proportion of pneumococcal meningitis and sepsis/bacteremia cases captured by SIREVA, by comparing the number of SIREVA-reported isolates in Argentina, Brazil, Chile, Colombia, Ecuador and Mexico with the estimated expected number of cases based on regional estimates of disease incidence. In all six countries, the number of isolates reported by SIREVA was consistently lower than the number of cases expected, across all years with data available. The proportion of SIREVA-reported isolates was highest in Chile (43–83%) and lowest in Mexico (1.4–3.5%). Passive surveillance systems such as SIREVA are important tools for monitoring circulating strains that could be related to pneumococcal disease, but our results show that SIREVA is likely to underestimate pneumococcal disease incidence. This under-reporting will limit the precision of surveillance data in monitoring changes in the incidence of IPD after vaccine introduction, and this should be considered when assessing the impact of vaccination programs. |
| first_indexed | 2024-03-11T21:42:41Z |
| format | Article |
| id | doaj.art-5b94aec46a454a80ba16e68808d6f3fd |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:41Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-5b94aec46a454a80ba16e68808d6f3fd2023-09-26T12:43:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-11-0117114667467210.1080/21645515.2021.19727091972709Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impactJavier Nieto Guevara0Adriana Guzman-Holst1GSK VaccinesGSK VaccinesDisease surveillance data are needed to monitor trends in disease activity, inform decision-making in public health and evaluate disease prevention/control measures. The Sistema Regional de Vacunas (SIREVA) supports laboratory-based surveillance of invasive pneumococcal disease (IPD) in Latin American countries, providing information on identification, distribution, and anti-microbial susceptibility of pneumococcal strains. We estimated the proportion of pneumococcal meningitis and sepsis/bacteremia cases captured by SIREVA, by comparing the number of SIREVA-reported isolates in Argentina, Brazil, Chile, Colombia, Ecuador and Mexico with the estimated expected number of cases based on regional estimates of disease incidence. In all six countries, the number of isolates reported by SIREVA was consistently lower than the number of cases expected, across all years with data available. The proportion of SIREVA-reported isolates was highest in Chile (43–83%) and lowest in Mexico (1.4–3.5%). Passive surveillance systems such as SIREVA are important tools for monitoring circulating strains that could be related to pneumococcal disease, but our results show that SIREVA is likely to underestimate pneumococcal disease incidence. This under-reporting will limit the precision of surveillance data in monitoring changes in the incidence of IPD after vaccine introduction, and this should be considered when assessing the impact of vaccination programs.http://dx.doi.org/10.1080/21645515.2021.1972709argentinabrazilchilecolombiaecuadormexicopneumococcal conjugate vaccinesinvasive pneumococcal diseasechildrensurveillance |
| spellingShingle | Javier Nieto Guevara Adriana Guzman-Holst Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact Human Vaccines & Immunotherapeutics argentina brazil chile colombia ecuador mexico pneumococcal conjugate vaccines invasive pneumococcal disease children surveillance |
| title | Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact |
| title_full | Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact |
| title_fullStr | Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact |
| title_full_unstemmed | Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact |
| title_short | Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact |
| title_sort | laboratory based surveillance in latin america attributes and limitations in evaluation of pneumococcal vaccine impact |
| topic | argentina brazil chile colombia ecuador mexico pneumococcal conjugate vaccines invasive pneumococcal disease children surveillance |
| url | http://dx.doi.org/10.1080/21645515.2021.1972709 |
| work_keys_str_mv | AT javiernietoguevara laboratorybasedsurveillanceinlatinamericaattributesandlimitationsinevaluationofpneumococcalvaccineimpact AT adrianaguzmanholst laboratorybasedsurveillanceinlatinamericaattributesandlimitationsinevaluationofpneumococcalvaccineimpact |